Jun. 14 at 7:40 PM
$VNRX [Again] First-in-World Liquid Biopsy technology, anchored by substantive Intellectual Property (below), proven through multiple papers and studies across more than 13 different cancer derivatives including lung and kidney.
$24B total addressable market, scalable, in commercial licensing negotiations with several companies ahead of reimbursement results. High Risk, High Reward again given the liquidity constraints of the Company -
$12M market cap with sufficient Cash now to cover 2026FYE. The SP could continue to fall here to
$1.0-1.2 as noted, with multiplier upside possible with successful licensing, adoption.
